Reimbursement Premiums Down In Japan
This article was originally published in PharmAsia News
Executive Summary
Both the volume and size of premiums given to drugs during the reimbursement process in Japan are down in 2012, according to analysis by L.E.K. Consulting, and it might not be a one-year anomaly.